APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Phase 1

Completed

• Conditions: Microsatellite Instability; Mismatch Repair Deficiency; Cancer of Unknown Primary Site; Solid Tumor
• Interventions: Drug: APL-501

• Registration Number: NCT03053466
• Lead Sponsor: Apollomics (Australia) Pty. Ltd.

Brief Summary

The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.

Detailed Description

This is a Phase 1, multicenter, 3-part study with a Dose-Escalation Segment, Cohort Extension and Dose and Disease Expansion cohorts of APL-501 injection, a humanized IgG4 monoclonal antibody, targeting the Programmed Death-1 (PD-1) membrane receptor on T lymphocytes and other cells of the immune system. Select advanced solid tumor malignancies will receive escalating doses of APL-501.

Dose escalation will occur in three subject cohorts until a protocol defined dose limited toxicity (DLT) occurs, not due to disease progression or inter-current illness, and a tentative maximum tolerated dose (MTD) or biologically effective dose (BED) is determined.

Cohort Extension will evaluate APL-501 at 3 mg/kg and 10 mg/kg on Day 1 and Day 15 every 28 days.

At the tentative MTD, BED or recommended Phase 2 dose (RP2D), at least two tumor types in the Dose and Disease Expansion will be assessed at an equivalent non-weight based dose to further evaluate toxicity and preliminary efficacy.

Study Timeline

• Study First Submitted: 2017-01-30
• Study First Submitted QC: 2017-02-12
• Study First Posted: 2017-02-15
• Study Start: 2017-03-27
• Primary Completion: 2022-02-25
• Study Completion: 2022-02-25
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-05
• Last Update Posted: 2022-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Able to understand and comply with study procedures, understand the risks involved, and provide written informed consent.

Dose Escalation:

• Histologically and / or cytological confirmed solid tumors: colorectal, endometrial, gastric including, gastroesophageal junction adenocarcinoma (GC), head and neck (esophageal, hepatocellular (HCC), non-small cell lung cancer, mesothelioma, ovarian, and renal cell carcinoma (RCC), either refractory or relapsed to standard therapy or for which no effective standard therapy is available.
• No restriction to number of prior therapies for Dose Escalation Segment except for gastric and renal cell carcinoma.

Cohort Extension:

• Histologically and/or cytological confirmed solid tumors with an approved labelled indication for PD-1 inhibitors.
• Tumor biopsy at study entry and during therapy. Tumor sites used to satisfy this criterion must not have received any prior radiation therapy. Sites for biopsy must be distinct from target lesions used for efficacy assessment.
• Measurable disease according to RECIST v1.1.

Dose and Disease Expansion:

• MSI-H or dMMR per local laboratory and failed at least one prior line of standard of care chemotherapy per local standards.
• Carcinoma of Unknown Primary

Major

Exclusion Criteria

• History of severe hypersensitivity to mAbs, excipients of the drug product or other components
• Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast
• Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways) (except NSCLC)
• Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the Investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single-Arm	APL-501	APL-501

Primary Outcome Measures

Name	Time	Method
Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors	From the time of informed consent from signature until Day 28 after Cycle 1; Dose Escalation - Approximately 9 months	Adverse events, serious adverse events, dose limiting toxicities according to the National Cancer Institute (NCI) Terminology Criteria for Adverse Events (CTCAE v4.03)

Secondary Outcome Measures

Name	Time	Method
Area under the plasma concentration versus time curve (AUC)	Up to 4 months (1 cycle = 28 days)	AUC, 0-infinity
Time to reach Cmax	Up to 4 months (1 cycle = 28 days)	Tmax
Objective Response Rate (ORR)	Approximately 24 months	The treatment effect of APL-501 will be assessed by RECIST v1.1 and by irRECIST to determine proportion of patients with complete response or partial response.
Determine the recommended Phase 2 dose and schedule	An average of 1 year	adverse events, serious adverse events, dose limiting toxicities
Maximum plasma concentration	Up to 4 months (1 cycle = 28 days)	Cmax
Duration of Response (DOR)	Approximately 24 months	The treatment effect of APL-501 will be assessed by RECIST v1.1 or by irRECIST to determine duration of response. Time from first documented complete response or partial response until subsequent documented disease progression or death.
Time to Response (TTR)	Approximately 24 months	The treatment effect of APL-501 will be assessed by RECIST v1.1 and by irRECIST to determine time to complete response and partial response.
Disease Control Rate (DCR)	Approximately 24 months	The treatment effect of APL-501 will be assessed by RECIST v1.1 and irRECIST to determine disease control rate. Proportion of patients with best overall response of complete response, partial response, or stable disease.
Progression Free Survival	Approximately 24 months	The effect of APL-501 will be assessed by RECIST v1.1 and per irRECIST to determine progression free survival as time from date of first dose to date of disease progression or death.

Trial Locations

Locations (5)

Nucleus Network; 🇦🇺 Melbourne, Victoria, Australia

Chris O'Brien Lifehouse; 🇦🇺 Camperdown, New South Wales, Australia

Linear Clinical Research; 🇦🇺 Nedlands, Western Australia, Australia

Peter MaCallum Cancer Centre; 🇦🇺 Melbourne, Victoria, Australia

Cabrini Health Limited; 🇦🇺 Malvern, Victoria, Australia